A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
A phase 1/2 trial of AZD4045, Daratumumab, Aldesleukin in multiple myeloma, run by AstraZeneca, now recruiting.
Overview
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07681596 by AstraZeneca, with 101 participants planned, started 2026-07-27 and due to reach its primary completion in 2031-03-06. Interventions recorded: AZD4045, Daratumumab, Aldesleukin. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialIDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Shares Aldesleukin (high-dose IL-2), Daratumumab, Multiple myeloma.
- TrialA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone
Shares Daratumumab, Multiple myeloma.
- TrialA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Shares Daratumumab, Multiple myeloma.
- TrialA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
Shares Daratumumab, AstraZeneca, Multiple myeloma.
- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Multiple myeloma.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Daratumumab, Multiple myeloma.
- TrialStudy of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Shares Daratumumab, AstraZeneca, Multiple myeloma.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Daratumumab, Multiple myeloma.